CD37: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 24: | Line 24: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | |||
__NOINDEX__ | |||
Latest revision as of 05:34, 17 March 2025
CD37 is a transmembrane protein that is primarily expressed on the surface of B cells, a type of white blood cell. It is a member of the tetraspanin superfamily, a group of proteins that span the cell membrane four times and are involved in various cellular processes.
Structure[edit]
The CD37 protein is composed of 295 amino acids and has a molecular weight of approximately 40 kiloDaltons. It has four transmembrane domains, two extracellular loops, and one intracellular loop. The large extracellular loop is thought to be involved in protein-protein interactions.
Function[edit]
CD37 is involved in several important cellular processes, including cell adhesion, signal transduction, and immune response. It plays a crucial role in the regulation of B cell function and development. CD37 is also involved in the process of apoptosis, or programmed cell death.
Clinical significance[edit]
Alterations in the expression of CD37 have been associated with various diseases, including autoimmune diseases and cancer. In particular, CD37 is often overexpressed in B cell lymphoma, a type of cancer that originates in the B cells. This has led to the development of therapeutic strategies that target CD37, such as monoclonal antibodies and immunotoxins.
Therapeutic potential[edit]
Several drugs that target CD37 are currently in clinical trials for the treatment of B cell lymphomas. These include BI 836826, a monoclonal antibody that binds to CD37 and triggers the death of cancer cells, and IMGN529, an antibody-drug conjugate that delivers a cytotoxic drug directly to cancer cells expressing CD37.
See also[edit]
